CAR-T cell therapy for resistant or relapsed multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new CAR-T cell therapy that targets FcRL5 on myeloma cells. It's for people whose myeloma has come back or stopped responding to other treatments, including stem cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- Your myeloma has returned or is not responding to treatment.
- You have tried other treatments like stem cell transplant, but they didn't work or you can't have one.
- Your liver function tests (ALT, AST) are less than 3 times the normal level.
- You are able to do daily activities with some help (KPS score over 50%).
- You do not have serious heart, liver, or kidney disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immunotherapy called CAR-T cells that target two proteins (BCMA and FcRL5) on myeloma cells. It is for people whose myeloma has returned or not responded to other treatments.
This trial tests a new kind of CAR-T cell therapy (called APRIL-BAFF-Bicephali CAR-T) for people with multiple myeloma that has come back or not responded to treatment. It aims to see if this therapy is safe and can help when other treatments have stopped working.
This trial tests a new treatment called CAR-T cell therapy for people with multiple myeloma that has come back or not responded to other treatments. The treatment uses your own immune cells, modified in a lab to attack the cancer, and may be an option after a stem cell transplant has not worked.
This early trial tests a new CAR-T cell treatment targeting three proteins (CD19, CD22, and BCMA) on myeloma cells. It's for people whose myeloma came back or didn't respond to at least three prior treatments.
This trial tests a new treatment that combines a stem cell transplant with special immune cells (called CAR-T cells) to fight multiple myeloma. The goal is to see if this combined approach helps people with newly diagnosed myeloma achieve better control of their disease.
This trial tests a new treatment called CAR-T cell therapy that uses your own immune cells to fight cancer. It is for people with multiple myeloma or plasma cell leukemia that has come back or not responded to other treatments.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.